Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Longevity Health Holdings has secured a temporary reprieve from Nasdaq delisting, but the clock is ticking as the ...